Spore in prostate cancer - overall project summary/abstract prostate cancer has become the most frequently diagnosed cancer in men in the united states (US) and a major cause of cancer morbidity and…

Active Project Grant Awarded Last action

Award ID
P50CA272391
Recipient
Awarding agency
Obligated
$6,719,675

Award facts

Assistance listing
93.397 Cancer Centers Support Grants
Completion date 44% complete
Place of performance
Baltimore, MD 21205, USA

Award details come from USAspending.gov.

Description

Spore in prostate cancer - overall project summary/abstract prostate cancer has become the most frequently diagnosed cancer in men in the united states (US) and a major cause of cancer morbidity and mortality, with 33,000 american men (~90 every day) dying annually from the disease. Considerable progress over the last decade resulted in the approval of multiple new hormonal and cytotoxic therapies, each producing modest improvement in survival. Yet, despite a broad palette of therapeutic options and the emerging promise of immunotherapy, the cure of metastatic prostate cancer has remained elusive. However, over the past two decades, dedicated prostate cancer research, accomplished by johns hopkins prostate cancer program investigators and other researchers, led to a remarkable accumulation of knowledge about the molecular mechanisms by which human prostate cancers arise and progress. These studies identified adaptive autoregulation of androgen receptor activity, mutations and alterations in DNA-repair pathways and an immunosuppressive microenvironment as fundamental characteristics of prostate cancer producing resistance to hormonal, DNA-targeted and immune based therapies and allowing for progression that eventually threatens life. To make significant advancement in the treatment of prostate cancer, the goal of this new prostate spore application is to translate new insights about the role played by adaptive changes in the hormonal axis, DNA-repair and the immune system in the pathobiology of prostate cancer into new hypotheses tested in clinical trials. The transcendent overall objective of the johns hopkins prostate cancer spore is to reduce prostate cancer mortality via the focused pursuit of translational research in prostate cancer.

Transactions

Action Obligated Date
Amendment $0
Amendment $2,264,776
Amendment $2,264,776
Amendment $0
Original award $2,190,123

Subawards

Subrecipient Amount Awarded
University Of Maryland, Baltimore SPORE in Prostate Cancer $132,660

Quick answers

Who received award P50CA272391?

P50CA272391 was awarded to The Johns Hopkins University by National Cancer Institute (National Institutes of Health) on September 1, 2024.

How much is award P50CA272391 worth?

$6,719,675 has been obligated on P50CA272391.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award